Functional imaging in lung cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-05-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.08.854PMID 15886307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.

  2005cited by this paper
• Improving the specificity of fluorescence bronchoscopy for the analysis of neoplastic lesions of the bronchial tree by combination with optical spectroscopy: preliminary communication.

  2005cited by this paper
• Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.

  2004cited by this paper
• Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging.

  2004cited by this paper
• Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

  2004cited by this paper
• FDG-PET in radiotherapy treatment planning: Pandora's box?

  2004cited by this paper
• Cancer Statistics, 2004

  2004cited by this paper
• Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging--perfusion differences in malignant and benign lesions.

  2004cited by this paper
• Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer.

  2004cited by this paper
• [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?

  2004cited by this paper
• Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?

  2004cited by this paper
• Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.

  2004cited by this paper
• Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

  2003cited by this paper
• Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

  2003cited by this paper
• Role of fusion in radiotherapy treatment planning.

  2003cited by this paper
• The solitary pulmonary nodule.

  2003cited by this paper
• Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.

  2003cited by this paper
• Pulmonary hilar lymph nodes in lung cancer: assessment with 3D-dynamic contrast-enhanced MR imaging.

  2003cited by this paper
• Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.

  2003cited by this paper
• In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM

  2003cited by this paper
• The noninvasive staging of non-small cell lung cancer: the guidelines.

  2003cited by this paper
• Optimizing radiation treatment plans for lung cancer using lung perfusion information.

  2002cited by this paper
• An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer.

  2002cited by this paper
• 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.

  2002cited by this paper
• The solitary pulmonary nodule.

  2002cited by this paper
• Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer.

  2002cited by this paper
• FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.

  2002cited by this paper
• Solitary pulmonary nodules: potential role of dynamic MR imaging in management initial experience.

  2002cited by this paper
• Prediction of postoperative lung function in patients with lung cancer: comparison of quantitative CT with perfusion scintigraphy.

  2002cited by this paper
• Prognostic value of [18F]FDG-PET imaging in small cell lung cancer

  2002cited by this paper
• Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.

  2002cited by this paper
• FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence.

  2002cited by this paper
• 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.

  2002cited by this paper
• Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy.

  2001cited by this paper
• Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review.

  2001cited by this paper
• Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.

  2001cited by this paper
• (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.

  2001cited by this paper
• The clinical value of lung imaging fluorescence endoscopy for detecting synchronous lung cancer.

  2001cited by this paper
• A tabulated summary of the FDG PET literature.

  2001cited by this paper
• The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer

  2000cited by this paper
• Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.

  2000cited by this paper
• [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer.

  2000cited by this paper
• Contrast-enhanced MRI of the lung.

  2000cited by this paper
• MR imaging of mediastinal lymph nodes: Evaluation using a superparamagnetic contrast agent

  2000cited by this paper
• Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

  2000cited by this paper
• Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.

  2000cited by this paper
• The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.

  2000cited by this paper
• 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis.

  1999cited by this paper
• Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

  1999cited by this paper
• Staging non-small cell lung cancer with whole-body PET.

  1999cited by this paper
• Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer.

  1999cited by this paper
• Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

  1999cited by this paper
• Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma

  1999cited by this paper
• Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.

  1999cited by this paper
• Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.

  1999cited by this paper
• Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects.

  1999cited by this paper
• Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.

  1998cited by this paper
• Imaging proliferation in vivo with [F-18]FLT and positron emission tomography

  1998cited by this paper
• Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group.

  1998cited by this paper
• The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer.

  1998cited by this paper
• The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

  1998cited by this paper
• Prospective investigation of positron emission tomography in lung nodules.

  1998cited by this paper
• Malignancy associated changes in bronchial epithelial cells and clinical application as a biomarker.

  1998cited by this paper
• Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.

  1997cited by this paper
• Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.

  1996cited by this paper
• A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma

  1996cited by this paper
• Cost-effectiveness of PET imaging in clinical oncology.

  1996cited by this paper
• Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.

  1996cited by this paper
• Detecting recurrent or residual lung cancer with FDG-PET.

  1995cited by this paper
• Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.

  1995cited by this paper
• Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).

  1995cited by this paper
• The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram.

  1995cited by this paper
• Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose.

  1994cited by this paper
• Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.

  1993cited by this paper
• Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes.

  1987cited by this paper
• Glossary of terms for thoracic radiology: recommendations of the Nomenclature Committee of the Fleischner Society.

  1984cited by this paper
• THE SOLITARY PULMONARY NODULE

  1957cited by this paper
• [Origin of cancer cells].

  1956cited by this paper
• On the origin of cancer cells.

  1956cited by this paper

• Contrast-enhanced computed tomography versus positron emission tomography/positron emission tomography-computed tomography in suspected lung cancer: a systematic review and meta-analysis of diagnostic accuracy studies

  2025cites this paper
• A Practical green synthesis for fluorescence carbon quantum dots via red Aloe barbadensis miller: antioxidant, anticancer and potential bioimaging applications

  2025cites this paper
• Exploring the diagnostic landscape: A narrative review of the evolving role and advancement of MRI in the detection and characterization of lung câncer

  2024cites this paper
• Biomarkers of immunotherapy in non-small cell lung cancer

  2020cites this paper
• Molecular Imaging of Pulmonary Inflammation and Infection

  2020cites this paper
• Diffusion-Weighted Magnetic Resonance Imaging for Early Detection of Chemotherapy Resistance in Non-Small Cell Lung Cancer

  2019cites this paper
• ePAD: An Image Annotation and Analysis Platform for Quantitative Imaging

  2019cites this paper
• Towards diagnostic and therapeutic integration of advanced MR imaging in thoracic and neuro-oncology

  2019cites this paper
• Lung cancer staging: a concise update

  2018cites this paper
• Performance Analysis of Image Processing Algorithms using Matlab for Biomedical Applications

  2017cites this paper
• Diagnostic and clinical application value of magnetic resonance imaging (MRI) for progressive massive fibrosis of coal worker pneumoconiosis

  2017cites this paper
• The Influence of Fat Suppression Technique on Diffusion-weighted (DW) MRI in Lung Cancer

  2017cites this paper
• The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis.

  2016cites this paper
• Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT

  2016cites this paper
• Dynamic Contrast-Enhanced CT in Patients with Pancreatic Cancer

  2016influential citation
• Ultrasmall [(64)Cu]Cu nanoclusters for targeting orthotopic lung tumors using accurate positron emission tomography imaging.

  2015cites this paper
• Caractérisation de populations tumorales dans les cancers bronchiques non à petites cellules en TEP au FDG en fonction de critères anatomopathologiques et génétiques

  2015cites this paper
• PET/MRI in lung cancer.

  2014cites this paper
• Automated tracking of quantitative assessments of tumor burden in clinical trials.

  2014cites this paper
• 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.

  2013cites this paper
• Functional imaging in lung cancer

  2013cites this paper
• SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin Lymphoma

  2012cites this paper
• Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

  2011cites this paper
• Molecular imaging in pulmonary diseases.

  2011influential citation
• Imaging of lung cancer in the era of molecular medicine.

  2011cites this paper
• Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study.

  2010cites this paper
• Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theory

  2010cites this paper
• Semiquantitative Visual Approach to Scoring Lung Cancer Treatment Response Using Computed Tomography: A Pilot Study

  2009cites this paper
• Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer.

  2009cites this paper
• Mediastinal Lymph Node Dissection Affects Survival in Patients with Stage I Non-Small Cell Lung Cancer

  2008cites this paper
• CT-guided automated detection of lung tumors on PET images

  2008cites this paper
• Qualitative radiology assessment of tumor response: does it measure up?

  2008cites this paper
• Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients.

  2008cites this paper
• Detection of small pulmonary nodules in high-field MR at 3 T: evaluation of different pulse sequences using porcine lung explants

  2007cites this paper
• Lung cancer.

  2007cites this paper
• Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT

  2007cites this paper
• FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.

  2007influential citation
• Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.

  2006cites this paper
• Integrin αvβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non–small-cell lung cancer models

  2006cites this paper
• Prognostic Usefulness of Maximum Standardized Uptake Value on FDG-PET in Surgically Resected Non-small-cell Lung Cancer

  2006cites this paper
• FDG PET And Adrenocortical Carcinoma: A Case Of Tumour Embolism

  2006cites this paper
• Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy.

  2006cites this paper
• Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy.

  2006cites this paper
• Short-Term Restaging of Patients with Non-small Cell Lung Cancer Receiving Chemotherapy

  2006cites this paper